Supplementary Information:

References used for snowballing ‘gene expression profiling’- related search terms

1. Gokmen-Polar Y, Badve S. Molecular profiling assays in breast cancer: Are we ready for prime time? Oncology (Williston Park). 2012 Apr;26(4):350,7, 361.
2. Wizemann T, Berger A, Roundtable on Translating Genomic-Based Research for Health, Board on Science-based Policy, Institute of Medicine. Generating evidence for genomic diagnostic test development: Workshop summary. Washington DC: The National Academies Press; 2011. Available: http://www.nap.edu/catalog.php?record\_id=13133 (accessed Oct 2013).
3. Marchionni L, Wilson RF, Wolff AC, Marinopoulos S, Parmigiani G, Bass EB, et al. Systematic review: Gene expression profiling assays in early-stage breast cancer. Ann Intern Med. 2008 Mar 4;148(5):358-69.

HTAs on cost effectiveness or economic assessment only that were excluded from the dataset:

1. Chen E, Tong KB, Malin JL. Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer. Am J Manag Care. 2010 Dec 1;16(12): e333-342.
2. Cosler LE, Lyman GH. Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. Cancer Invest. 2009. 27 (10): 953-9.
3. Harris A, Johnston K, Lodge M. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technology Assessment. 2006. 10(34), 1-222, NIHR Health Technology Assessment programme.
4. Hornberger J, Cosler L, Lyman G. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node–negative, estrogen-receptor–positive, early-stage breast cancer. Am J Manag Care. 2005. 11:313-324.
5. Klang SH, Hammerman A, Liebermann N, Efrat N, Doburne J, Hornberger J. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed healthcare organization. Value Health. 2010. 13(4): 381-7.
6. Kondo M, Hoshi SL, Yamanaka T, Ishiguo H, Toi M. Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Research and Treatment. 2011. 127(3): 739-49.
7. Kondo M, Hoshi SL, Ishiguo H, Toi M. Economic evaluation of the 70-gene signature (Mammaprint) in hormone receptor-positive, lymph node-negative, Human epidermal growth factor type-2 negative early-stage breast cancer in Japan. Breast Cancer Research and Treatment. 2012. 133(2): 759-68.
8. Tsoi D, Inoue M, Kelly C, Verma S, Pritchard K. Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer. Oncologist. 2010. 15(5): 457–465.
9. Kondo M, Hoshi SL, Ishiguo H, Yoshibayashi H, Toi M. Economic evaluation of the 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor positive, early-stage breast cancer in Japan. Breast Cancer Research and Treatment. 2008. 112(1): 175-87.
10. Lyman GH, Kuderer NM. Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: a meta-analysis. Clin Breast Cancer. 2006. 7(5):372-9.
11. Lyman GH, Cosler LE, Kuderer NM, Hornberger J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer. 2007. 109(6):1011-8.
12. Williams C, [Brunskill S](http://www.ncbi.nlm.nih.gov/pubmed?term=Brunskill%20S%5BAuthor%5D&cauthor=true&cauthor_uid=16959170), [Altman D](http://www.ncbi.nlm.nih.gov/pubmed?term=Altman%20D%5BAuthor%5D&cauthor=true&cauthor_uid=16959170), [Briggs A](http://www.ncbi.nlm.nih.gov/pubmed?term=Briggs%20A%5BAuthor%5D&cauthor=true&cauthor_uid=16959170), [Campbell H](http://www.ncbi.nlm.nih.gov/pubmed?term=Campbell%20H%5BAuthor%5D&cauthor=true&cauthor_uid=16959170), [Clarke M](http://www.ncbi.nlm.nih.gov/pubmed?term=Clarke%20M%5BAuthor%5D&cauthor=true&cauthor_uid=16959170), [Glanville J](http://www.ncbi.nlm.nih.gov/pubmed?term=Glanville%20J%5BAuthor%5D&cauthor=true&cauthor_uid=16959170), [Gray A](http://www.ncbi.nlm.nih.gov/pubmed?term=Gray%20A%5BAuthor%5D&cauthor=true&cauthor_uid=16959170), [Harris A](http://www.ncbi.nlm.nih.gov/pubmed?term=Harris%20A%5BAuthor%5D&cauthor=true&cauthor_uid=16959170), [Johnston K](http://www.ncbi.nlm.nih.gov/pubmed?term=Johnston%20K%5BAuthor%5D&cauthor=true&cauthor_uid=16959170), [Lodge M](http://www.ncbi.nlm.nih.gov/pubmed?term=Lodge%20M%5BAuthor%5D&cauthor=true&cauthor_uid=16959170). Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess. 2006. 10(34): 1-204.
13. Oestreicher N, Ramsey S, Linden H, McCune J, van’t Veer L, Burke W, Veenstra D. Gene expression profiling and breast cancer care: What are the potential benefits and policy implications? 2005. Genetics in Medicine. 7(6) 380-389.

Excluded HTAs in languages other than English

1. Aguado Romeo MJ, Llanos Mendez A. Prueba de expresion genetica en el cancer de mama Oncotype. Informe de sintesis de tecnologia emergente. [Gene expression test for breast cancer Oncotype] Seville: Andalusian Agency for Health Technology Assessment (AETSA). AETSA 2007/2-20. 2010.
2. M. Cuadros and A. Llanos. [Validation and clinical application of MammaPrint((R)) in patients with breast cancer.] Medicina Clinica. 2011. 136(14):627-32.

Evidence report and evidence overview supporting NICE Diagnostics Advisory Committee Provisional recommendations. 2012 (ref #24)(included in study HTAs).

1. Ward, S, Scope, A, Rafia, R, Pandor, A, Harnan, S and Evans, P. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management. Health Technol Assess. 2012. 1-280.
2. NICE Diagnostics Advisory Committee. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat: Evidence Overview. NHS National Institute For Health and Clinical Excellence (Internet). 2011. 1-50.

Document excluded because it had been previously published as an AHRQ evidence document 2008 (ref #25)(included in study HTAs).

1. Marchionni L, Wilson RF, Wolff AC, Marinopoulos S, Parmigiani G, Bass EB, et al. Systematic review: Gene expression profiling assays in early-stage breast cancer. Ann Intern Med. 2008 Mar 4;148(5):358-69.